Megace

Megestrol Acetate, the active ingredient in Megace, is a progestin presented as an oral tablet for oral use. It is employed to stimulate appetite and to provide hormone therapy in certain cancer indications, particularly in patients with cachexia related to AIDS or advanced malignancies.

GNH USA supplies Megace as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across multiple markets, and providing reliable logistics for global distribution.

Megace is a synthetic progestogen used in oncology and supportive care to address disease‑related weight loss and hormone‑sensitive tumors. - Cachexia associated with AIDS or cancer: improves appetite and promotes weight gain in affected patients. - Advanced breast cancer: provides antineoplastic activity in hormone‑responsive disease. - Endometrial cancer: used as hormonal therapy for disease control.

Megace may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Weight gain: primarily due to increased appetite. - Edema: peripheral swelling, often mild. - Fatigue: generalized tiredness. - Hot flashes: transient vasomotor symptoms. - Mood changes: irritability or mild depression.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Adrenal insufficiency: cortisol suppression with abrupt withdrawal. - Hyperglycemia: elevated blood glucose, especially in diabetics. - Hepatotoxicity: abnormal liver enzymes or hepatic dysfunction. - Severe allergic reaction: rash, angioedema, or anaphylaxis.

Before initiating therapy, clinicians should evaluate patient history and monitor for potential complications. - Assess risk of thromboembolism: consider prophylaxis in high‑risk individuals. - Monitor blood glucose: adjust diabetic therapy as needed. - Evaluate liver function: periodic tests for hepatotoxicity. - Watch for adrenal suppression: taper dose gradually when discontinuing. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Megace can alter the pharmacokinetics or pharmacodynamics of several agents; careful review of concomitant medications is advised.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - CYP3A4 inducers (e.g., rifampin): reduced megace exposure.

Moderate Interactions (Monitor Closely): - Antidiabetic drugs: potential for hyperglycemia, monitor glucose levels. - Corticosteroids: additive adrenal suppression, assess adrenal function. - Hormonal contraceptives: decreased efficacy, consider alternative contraception.